myTomorrows unveils AI search tool to deliver clinical trials to patients
The search tool is being launched by myTomorrows in beta version, and is known as TrialSearch AI. The company suggests that the tool can help broaden physician insights into clinical trials and expanded access programs, with myTomorrows noting that the database is curated for investigational pre-approval options sourced from public registries.
myTomorrows stated that its TrialSearch AI reduces pre-screening checking time by up to 90% for treating physicians. The technology itself is based on the GPT series of LLM AI models developed by OpenAI, the company behind the ChatGPT platform that surged to celebrity in recent months.
The tool searches worldwide for potential treatment pathways, giving physicians a breakdown of pre-approval options for patients who may be eligible. The tool can then filter exclusion criteria based on input of information on the patient’s condition and profile by the healthcare professional (HCP).
TrialSearch allows for the creation of a patient profile through the entering of basic and de-identified information, such as the patient’s condition, age, sex, and country of residence, alongside other health information. Once entered, the search tool provides a list of clinical trials, and potential expanded access programs, that may be promising for patients.
Once the list of clinical trials is generated, the physician is required to complete a series of manual checks to ensure that the responses are suitable to the patient. myTomorrows stated that the process of searching, reviewing, and referring patients can be completed in a matter of minutes.
“Our team of researchers and developers designed TrialSearch AI to bring greater speed, transparency, and accuracy to the complex, time-consuming task of manually searching for clinical trials. As a physician who cared for patients diagnosed with cancer, I know first-hand the importance of providing actionable information that can help physicians, patients, and caregivers discover and access potentially life-saving treatments,” said Michel van Harten, CEO at myTomorrows.
Being at the Beta stage, the company is currently accepting requests from HCPs to trial the tool. At present, the tool has been used to connect over 5,000 patients to clinical trials, and has been used by over 500 physicians. The database of clinical research is populated by over 300,000 studies, which are being completed in over 175 countries.
In terms of the services it offers directly to pharma companies, myTomorrows states that it can manage expanded access programs, provide real-world data support, and provide patient finding services.
